

Clinical Oversight Review Board (CORB) Criteria for Prescribing Goserelin (Zoladex)

Notes:

- * Leuprolide intolerance excludes hot flashes and local injection site reactions
- If used for estradiol suppression in women, the dose must be 3.6 mg once monthly as there is insufficient data to support the reliability of using the 10.8 mg dose every 3 months for this indication

Non-Formulary **goserelin (Zoladex)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria:

- Patient is at least 18 years of age
-AND-
- Patient has a diagnosis of prostate cancer -OR- breast cancer -OR- endometrial thinning -OR- endometriosis
-AND-
- Normal QT interval on electrocardiogram
-AND-
- Documented treatment failure after an adequate trial of leuprolide or intolerance* to leuprolide. Leuprolide trial must include trying the 1-month and a multiple month depot (e.g., 3-month, 4-month, or 6-month). For patients who are male (sex assigned at birth) and being treated for breast cancer, leuprolide trial must include only the 1-month depot.

Criteria for *current Kaiser Permanente members already taking the medication who have not been reviewed previously:*

- Patient is at least 18 years of age
-AND-
- Patient has a diagnosis of prostate cancer -OR- breast cancer -OR- endometrial thinning -OR- endometriosis
-AND-
- Normal QT interval on electrocardiogram
-AND-
- Documented treatment failure after an adequate trial of leuprolide or intolerance* to leuprolide. Leuprolide trial must include trying the 1-month and a multiple month depot (e.g., 3-month, 4-month, or 6-month). For patients who are male (sex assigned at birth) and being treated for breast cancer, leuprolide trial must include only the 1-month depot.

kp.org

Revised: 09/14/23
Effective: 11/16/23

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest

Clinical Oversight Review Board (CORB) Criteria for Prescribing Goserelin (Zoladex)

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously:

- Patient is at least 18 years of age
-AND-
- Patient has a diagnosis of prostate cancer -OR- breast cancer -OR- endometrial thinning -OR- endometriosis
-AND-
- Normal QT interval on electrocardiogram
-AND-
- Documented treatment failure after an adequate trial of leuprolide or intolerance* to leuprolide. Leuprolide trial must include trying the 1-month and a multiple month depot (e.g., 3-month, 4-month, or 6-month). For patients who are male (sex assigned at birth) and being treated for breast cancer, leuprolide trial must include only the 1-month depot.